Does Rallies show Form 4 insider transactions for VVOS?

Yes. Rallies tracks VVOS insider trading and Form 4 activity, including executive purchases, executive sales, transaction dates, shares, and prices when available.

Is VVOS research on Rallies investment advice?

No. Rallies provides research, data, and educational context for VVOS. It does not provide personalized investment advice.

VVOS (Vivos Therapeutics, Inc. Common Stock) Stock Analysis - Insider Trades

Vivos Therapeutics, Inc. Common Stock (VVOS) is a publicly traded Healthcare sector company. As of May 21, 2026, VVOS trades at $0.58 with a market cap of $8.21M and a P/E ratio of -0.29. VVOS moved -0.85% today. Year to date, VVOS is -76.11%; over the trailing twelve months it is -72.49%. Its 52-week range spans $0.57 to $7.95. Analyst consensus is buy with an average price target of $2.42. Rallies surfaces VVOS's financials, insider trades, hedge fund holdings, congressional trades, analyst ratings, and AI-generated research below.

Who is trading VVOS stock inside the company?

Recent VVOS insider activity includes Skaff Michael C bought 1.04M, Skaff Michael C bought 308.85K, Huntsman Ronald Kirk bought 14.00K, Huntsman Ronald Kirk bought 10.00K, and Huntsman Ronald Kirk bought 5.00K. Rallies tracks insider transaction dates, shares, prices, and estimated values.

VVOS Key Metrics

Key financial metrics for VVOS
Metric	Value
Price	$0.58
Market Cap	$8.21M
P/E Ratio	-0.29
EPS	$-2.07
Dividend Yield	0.00%
52-Week High	$7.95
52-Week Low	$0.57
Volume	50.59K
Avg Volume	0
Revenue (TTM)	$17.44M
Net Income	$-21.23M
Gross Margin	60.44%

Recent VVOS Insider Trades

Skaff Michael C bought 1.04M (~$1.40M) on Mar 31, 2026.
Skaff Michael C bought 308.85K (~$413.86K) on Mar 31, 2026.
Huntsman Ronald Kirk bought 14.00K (~$7.42K) on Jun 20, 2023.
Huntsman Ronald Kirk bought 10.00K (~$5.40K) on Jun 16, 2023.
Huntsman Ronald Kirk bought 5.00K (~$2.65K) on Jun 16, 2023.

Latest VVOS News

Vivos Therapeutics Q1 Revenue Up 70%, Gross Margin Rises to 60% — May 20, 2026
Vivos Therapeutics Price Target Slashed to $2.50 as 2025 Revenue Jumps 16% — Apr 17, 2026
Vivos Liabilities Rise to $26.7M While Revenue Grows 16% in 2025 — Apr 16, 2026
Vivos CARE Devices Gain 510(k) Nod as Study Links Narrow Arches to Higher AHI — Mar 17, 2026

VVOS Analyst Consensus

3 analysts cover VVOS: 0 strong buy, 2 buy, 1 hold, 0 sell, 0 strong sell. Consensus rating is buy. Average price target: $2.42.

Common questions about VVOS

Who is trading VVOS stock inside the company?: Recent VVOS insider activity includes Skaff Michael C bought 1.04M, Skaff Michael C bought 308.85K, Huntsman Ronald Kirk bought 14.00K, Huntsman Ronald Kirk bought 10.00K, and Huntsman Ronald Kirk bought 5.00K. Rallies tracks insider transaction dates, shares, prices, and estimated values.
Does Rallies show Form 4 insider transactions for VVOS?: Yes. Rallies tracks VVOS insider trading and Form 4 activity, including executive purchases, executive sales, transaction dates, shares, and prices when available.
Is VVOS research on Rallies investment advice?: No. Rallies provides research, data, and educational context for VVOS. It does not provide personalized investment advice.